Table 1 Patient demographics and disease characteristics

From: Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

Parameter

Schedule 1 (n = 20)

Schedule 2 (n = 38)

All patients (n = 58)

Age, years

 Median (range)

61.0 (33−75)

62.5 (40−70)

62.0 (33−75)

Sex, n (%)

 Male

11 (55.0)

9 (23.7)

20 (34.5)

 Female

9 (45.0)

29 (76.3)

38 (65.5)

Race, n (%)

 White

19 (95.0)

36 (94.7)

55 (94.8)

 Black or African American

1 (5.0)

1 (2.6)

2 (3.4)

 Other

0

1 (2.6)

1 (1.7)

ECOG PS, n (%)

 0

4 (20.0)

16 (42.1)

20 (34.5)

 1

16 (80.0)

22 (57.9)

38 (65.5)

Prior systemic therapies, n (%)

 1

6 (30.0)

4 (10.5)

10 (17.2)

 2

9 (45.0)

7 (18.4)

16 (27.6)

 3

3 (15.0)

12 (31.6)

15 (25.9)

 4

1 (5.0)

4 (10.5)

5 (8.6)

 5−14

1 (5.0)

11 (28.9)

12 (20.7)

Tumour type, n (%)

 Breast

1 (5.0)

9 (23.7)

10 (17.2)

 Cholangiocarcinoma

2 (10.0)

0

2 (3.4)

 Colorectala

2 (10.0)

9 (23.7)

11 (19.0)

 Endometrial

1 (5.0)

6 (15.8)

7 (12.1)

 Gall bladder

2 (10.0)

0

2 (3.4)

 NSCLC

1 (5.0)

2 (5.3)

3 (5.2)

 Ovarian

0

10 (26.3)

10 (17.2)

 Pancreatic

2 (10.0)

1 (2.6)

3 (5.2)

 Pleural mesothelioma

3 (15.0)

0

3 (5.2)

 Uterine cervix

3 (15.0)

0

3 (5.2)

 Otherb

3 (15.0)

1 (2.6)

4 (6.9)

  1. aIncludes colon, rectum and large intestine (excludes appendix)
  2. bIncludes adrenal glands, duodenal, oesophageal and laryngeal cancers.
  3. ECOG PS Eastern Cooperative Oncology Group performance score, NSCLC non–small-cell lung cancer
Back to article page